MISSISSAUGA, Ontario, Feb. 22, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care™ Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan. A patent application for the "core technology" is currently pending in the U.S. before the United States Patent & Trademark Office (USPTO).
Yahia Gawad, MD, Chief Executive Officer of CardioGenics Holdings Inc. said, "We are very pleased that the patent offices of Canada, the European Union and Japan have acknowledged the unique nature of the 'core technology' upon which our QL Care™ Analyzer is based."
"The granting of these patents in these major commercial markets further enhances the value of CardioGenics' intellectual property portfolio and we now look forward to a similar disposition of our patent application for the 'core technology' from the USPTO," continued Dr. Gawad.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's